, July 8, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, is pleased to note the announcement from its partner Almirall S.A. that Sativex® is now available in
as a prescription medicine for use in the treatment of moderate to severe spasticity in Multiple Sclerosis (MS) patients who have not responded adequately to other anti-spasticity medications. The launch follows receipt of full marketing authorization for Sativex® by the Italian health authorities in May. The medicine is reimbursed by the Italian authorities as a Class H (hospital dispensed) medicine. The reimbursed price of the medicine granted by the authorities in
is consistent with the reimbursed Sativex® price in
"As one of the largest markets in
, the launch of Sativex® in
is a key milestone in the commercialization of this important new medicine.
represents yet another addition to the growing number of countries in
in which Sativex® is now available to treat MS spasticity, a particularly debilitating symptom of MS that is not adequately treated with currently available medications," stated
, Chief Executive Officer of GW. "With a total of 21 countries that have now approved Sativex
for use in the treatment of MS spasticity, and a further 9 countries in which regulatory submissions are ongoing, we look forward to a series of further commercial launches over the coming twelve months."
The full text of Almirall's announcement is below. (NOTE: the following press release issued by Almirall S.A. is translated into English for the convenience of the reader. Some variation may have occurred in this translation.)